Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma

Head and Neck

Volumn 28, Issue 11, 2006, Pages 1032-1039

  Rodrigo, Juan Pablo ^a,b   Rinaldo, Alessandra ^c   Devaney, Kenneth O ^d   Shaha, Ashok R ^e   Ferlito, Alfio ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d Foote Health System   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnosis; Follow up; Molecular diagnostic methods; Thyroid cancer; Well differentiated thyroid carcinoma

Indexed keywords

CD44V6 ANTIGEN; CYCLOOXYGENASE 2; FIBRONECTIN; GALECTIN 3; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; TELOMERASE; THYROGLOBULIN;

ACCURACY; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CELL DIFFERENTIATION; DISEASE MARKER; FOLLOW UP; HUMAN; IMMUNOASSAY; MOLECULAR BIOLOGY; NEEDLE BIOPSY; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SENSITIVITY ANALYSIS; SURGICAL TECHNIQUE; THYROID CARCINOMA; THYROID NODULE;

ANTIGENS, CD44; BIOPSY, FINE-NEEDLE; CYCLOOXYGENASE 2; FIBRONECTINS; GALECTIN 3; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HMGA1A PROTEIN; HUMANS; MEMBRANE PROTEINS; MOLECULAR DIAGNOSTIC TECHNIQUES; TELOMERASE; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750284688     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20411     Document Type: Review

References (80)

1. Shaha AR, Ferlito A, Rinaldo A. Thyroid cancer: a unique human neoplasm. Acta Otolaryngol 2002;122:343-347.
2. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75:338-352.
3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
4. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553-3562.
5. Nunez C, Mendelsohn G. Fine-needle aspiration and needle biopsy of the thyroid gland. Pathol Annu 1989;24:161-198.
6. Sidawy MK, Del Vecchio DM, Knoll SM. Fine-needle aspiration of thyroid nodules. Correlation between cytology and histology and evaluation of discrepant cases. Cancer 1997;81:253-259.
7. Bartolazzi A. Improving accuracy of cytology for nodular thyroid lesions. Lancet 2000;355:1661-1662.
8. Ferlito A, Boccato P, Shaha AR, Carbone A, Noyek AM, Doglioni C, Bradley PJ, Rinaldo A. The art of diagnosis in head and neck tumors. Acta Otolaryngol 2001;121:324-328.
9. Fernández PL, Merino MJ, Gómez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997;181:80-86.
10. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.
11. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998;58;3015-3020.
12. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-3502.
13. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-2484.
14. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
15. Oestreicher-Kedem Y, Halpern M, Roizman P, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004;26:960-966.
16. Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest 2004;27:311-317.
17. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol 2004;31:392-396.
18. Nucera C, Mazzon E, Caillou B, et al. Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest 2005;28:106-112.
19. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005;12:305-317.
20. Feilchenfeldt J, Totsch M, Sheu SY, et al. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol 2003;16:1117-1123.
21. Mehrotra P, Okpokam A, Bouhaidar R, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004;45:493-500.
22. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 2004;122:524-531.
23. Mills LJ, Poller DN, Yiangou C. Galectin-3 is not useful in thyroid FNA. Cytopathology 2005;16:132-138.
24. Takano T, Sumizaki H, Amino N. Detection of CD44 variants in fine needle aspiration biopsies of thyroid tumor by RT-PCR. J Exp Clin Cancer Res 1997;16:267-271.
25. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68.
26. Haugen BR, Nawaz S, Markham N, et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid 1997;7:337-342.
27. Yashima K, Vuitch F, Gazdar AF, Fahey TJ III. Telomerase activity in benign and malignant thyroid diseases. Surgery 1997;122:1141-1146.
28. Brousset P, Chaouche N, Leprat F, et al. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 1997;82:4214-4216.
29. Cheng AJ, Lin JD, Chan T, Wang TC. Telomerase activity in benign and malignant thyroid tissues. Br J Cancer 1998;77:2177-2180.
30. Onoda N, Ishikawa T, Yoshikawa K, et al. Telomerase activity in thyroid tumors. Oncol Rep 1998;5:1447-1450.
31. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 1997;57:2144-2147.
32. Saji M, Westra WH, Chen H, et al. Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. Surgery 1997;122:1137-1140.
33. Saji M, Xydas S, Westra WH, et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 1999;5:1483-1489.
34. Zeiger MA, Smallridge RC, Clark DP, et al. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Surgery 1999;126:1195-1198.
35. Sebesta J, Brown T, Williard W, et al. Does telomerase activity add to the value of fine needle aspirations in evaluating thyroid nodules? Am J Surg 2001;181:420-422.
36. Trulsson LM, Velin AK, Herder A, Soderkvist P, Ruter A, Smeds S. Telomerase activity in surgical specimens and fine-needle aspiration biopsies from hyperplastic and neoplastic human thyroid tissues. Am J Surg 2003;186:83-88.
37. Umbricht CB, Conrad GT, Clark DP, et al. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin Cancer Res 2004;10:5762-5768.
38. Kammori M, Nakamura K, Hashimoto M, Ogawa T, Kaminishi M, Takubo K. Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. Int J Oncol 2003;22:985-991.
39. Mora J, Lerma E. Telomerase activity in thyroid fine needle aspirates. Acta Cytol 2004;48:818-824.
40. Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 2003;191:223-227.
41. Ito Y, Yoshida H, Tomoda C, et al. Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Res 2005;25:509-514.
42. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58:4193-4198.
43. Czyz W, Balcerczak E, Jakubiak M, Pasieka Z, Kuzdak K, Mirowski M. HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma. Langenbecks Arch Surg 2004;389:193-197.
44. Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N. Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res 1997;57:3792-3797.
45. Takano T, Matsuzuka F, Miyauchi A, et al. Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study. Br J Cancer 1998;78:221-224.
46. Takano T, Miyauchi A, Yokozawa T, et al. Accurate and objective preoperative diagnosis of thyroid papillary carcinomas by reverse transcription-PCR detection of oncofetal fibronectin messenger RNA in fine-needle aspiration biopsies. Cancer Res 1998;58:4913-4917.
47. Takano T, Miyauchi A, Yokozawa T, et al. Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-polymerase chain reaction of oncofetal fibronectin messenger RNA. Cancer Res 1999;59:4542-4545.
48. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ III. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002;87:358-363.
49. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992;23:107-116.
50. Miettinen M, Kärkkäínen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumors. Preferential reactivity with malignant tumors. Virchows Arch 1996;429:213-219.
51. Mase T, Funahashi H, Koshikawa T, et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 2003;50:173-177.
52. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 2003;14:55-60.
53. Ito Y, Yoshida H, Tomoda C, et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 2005;25:179-182.
54. Rossi ED, Raffaelli M, Minimo C, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 2005;105:87-95.
55. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18:48-57.
56. Barden CB, Shister KW, Zhu B, et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003;9:1792-1800.
57. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ III. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-3223.
58. Finley DJ, Zhu B, Barden CB, Fahey TJ III. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 2004;240:425-436.
59. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 2003;338:297-306.
60. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-863.
61. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004;89:3702-3704.
62. Ditkoff BA, Marvin MR, Yemul S, et al. Detection of circulating thyroid cells in peripheral blood. Surgery 1996;120:959-965.
63. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-4442.
64. Tallini G, Ghossein RA, Emanuel J, et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. J Clin Oncol 1998;16:1158-1166.
65. Biscolla RPM, Cerutti JM, Maciel RMB. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. J Clin Endocrinol Metab 2000;85:3623-3627.
66. Chinnappa P, Taguba L, Arciaga R, et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004;89:3705-3709.
67. Bojunga J, Roddiger S, Stanisch M, et al. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br J Cancer 2000;82:1650-1655.
68. Bugalho MJ, Domingues RS, Pinto AC, et al. Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-413.
69. Fugazzola L, Mihalich A, Persani L, et al. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. J Clin Endocrinol Metab 2002;87:3201-3208.
70. Bellantone R, Lombardi CP, Bossola M, et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-2279.
71. Grammatopoulos D, Elliott Y, Smith SC, et al. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. Mol Pathol 2003;56:162-166.
72. Savagner F, Rodien P, Reynier P, Rohmer V, Bigorgne JC, Malthiery Y. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. J Clin Endocrinol Metab 2002;87:635-639.
73. Ringel MD, Balducci-Silano PL, Anderson JS, et al. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4037-4042.
74. Eszlinger M, Neumann S, Otto L, Paschke R. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol 2002;147:575-582.
75. Wingo ST, Ringel MD, Anderson JS, et al. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin Chem 1999;45:785-789.
76. Mercken L, Simons MJ, Brocas H, Vassart G. Alternative splicing may be responsible for heterogeneity of thyroglobulin structure. Biochimie 1989;71:223-226.
77. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000;36:1681-1694.
78. Ringel MD. Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. J Clin Endocrinol Metab 2004;89:29-32.
79. Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004;89:33-39.
80. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002;29:23-39.